SCHEMBL3536992

SCHEMBL3536992

CN1CCN(c2ccc3[nH]c(-c4ccc5[nH]nc(-c6nc7ccc(N8CCN(C)CC8)cc7[nH]6)c5c4)nc3c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.73
FLT1 P17948 2/20 0.73
TERT O14746 4/20 0.63
ALDH1A1 P00352 4/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
TOP1 P11387 3/20 0.61
TOP2A P11388 3/20 0.61
HPGD P15428 1/20 0.61
HSD17B10 Q99714 1/20 0.61
KDR P35968 2/20 0.59
PDGFRA P16234 1/20 0.59
FGFR2 P21802 1/20 0.59
FGFR4 P22455 1/20 0.59
FGFR3 P22607 1/20 0.59
FLT3 P36888 1/20 0.59
CDK4 P11802 1/20 0.59
CCNA2 P20248 1/20 0.59
CCND1 P24385 1/20 0.59
CDK2 P24941 1/20 0.59
CCND3 P30281 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542101 0.94 FGFR1 (0.80) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL15868925 0.94 FGFR1 (0.80) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL3536819 0.93 FGFR1 (0.71) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL14892593 0.88 FGFR1 (0.76) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL14906539 0.88 FGFR1 (0.90) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL3542673 0.86 FGFR1 (0.70) FGFR1FLT1ALDH1A1SMN1; SMN2TOP1
SCHEMBL3540318 0.86 FGFR1 (0.80) FGFR1FLT1TERTALDH1A1SMN1; SMN2
SCHEMBL31006250 0.86 FGFR1 (0.76) FGFR1FLT1ALDH1A1SMN1; SMN2TOP1
SCHEMBL3535921 0.86 FGFR1 (0.76) FGFR1FLT1ALDH1A1SMN1; SMN2TOP1
SCHEMBL3538752 0.85 FGFR1 (0.64) FGFR1FLT1ALDH1A1SMN1; SMN2TOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885TERT 885/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885TERT 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.